Complexo Hospitalario Universitario A Coruña

A Coruña 15006

3 studies enrolling now · 13 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Solid Tumors, Advanced/Metastatic Non-Small Cell Lung Cancer, Arthritis, Rheumatoid, Breast Cancer, Breast Neoplasms, C. Diff Infection, C.Difficile Diarrhea, CDI, Clostridioides Difficile Infection

Studies at this site

• VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) — Recruiting now
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
• INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Running, not enrolling
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) — Completed
• A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation — Stopped early
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors — Completed
• Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate — Completed
• Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy — Completed
• Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone — Stopped early
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. — Completed
• Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis — Completed